Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection

Zhiguang Guo, Tao Wu, Nicole Kirchhof, Deepak Mital, James W. Williams, Miyuki Azuma, David E.R. Sutherland, Bernhard J. Hering

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Abstract

Background. T-cell activation and the subsequent induction of effector functions require not only the recognition of antigen peptides bound to MHC molecules by T-cell receptor (TCR) for antigen but also a costimulatory signal provided by antigen presenting cells. CD4 T-cell activation and function require the CD4 molecule as a coreceptor of TCR. The CD28/B7 pathway is a major costimulatory signal for T-cell activation and differentiation. Methods. The effect of targeting CD4 by nondepleting anti-CD4 monoclonal antibodies (mAbs) versus and xenogeneic graft rejection. The efficacy of nondepleting anti-CD4 mAbs is compromised when it combines with CTLA4Ig.

Original languageEnglish (US)
Pages (from-to)1656-1665
Number of pages10
JournalTransplantation
Volume71
Issue number11
DOIs
StatePublished - Jun 15 2001

Fingerprint

Dive into the research topics of 'Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection'. Together they form a unique fingerprint.

Cite this